Aehr Test Systems (AEHR) Stock Analysis and Metrics

Aehr Test Systems

NASDAQ: AEHR

$67.87 ▲ +0.93 (+1.39%)

At close: Jul 8, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap2.59 Bn

P/E-227.01

P/S57.27

Div. Yield0.00

ROIC (Qtr)0.00

Revenue Growth (1y) (Qtr)-43.67

Add ratio to table…

About

Aehr Test Systems, Inc. is a leading provider of test solutions for testing, burning‑in, and stabilizing semiconductor devices in wafer level, singulated die, and package form. The company serves mission‑critical applications such as artificial intelligence compute data centers, electric vehicles, electric vehicle charging infrastructure, solar and wind power, data and telecommunications infrastructure, and solid‑state memory storage. Its products enable customers to improve quality, reliability, safety, and security of semiconductors used in these high‑growth markets, including leading‑edge silicon carbide‑based and gallium nitride power semiconductors, 2D and 3D sensors for mobile devices, memory semiconductors, processors, system‑on‑a‑chip, and photonics and integrated optical devices for AI.

Revenue is generated primarily from the sale of full wafer contact test systems, wafer‑level burn‑in and test solutions, and packaged‑part burn‑in systems, along with related services and spare parts. The company’s product families include the FOX‑XP, FOX‑NP, FOX‑CP platforms, wafer‑level contactors such as the WaferPak Contactor, die‑level carriers like the DiePak Carrier, and the Incal‑acquired Sonoma, Tahoe and Echo package‑part burn‑in lines. In fiscal 2025, full wafer contact product lines generated $39.2 million, representing approximately 66% of net revenues, while packaged‑part product lines contributed $19.8 million, or about 34% of net revenues.

The company operates through the following segments:

• Advanced Test and Burn‑in Products: This segment encompasses the design, manufacture, marketing and sale of advanced test and burn‑in solutions for semiconductor devices, including wafer‑level test and burn‑in systems, packaged‑part burn‑in systems, wafer‑level contactors, die‑level carriers and associated services that serve a broad range of end markets such as AI, power semiconductors, photonics and sensors.

Aehr Test Systems holds a strong niche position in the semiconductor test equipment market by offering proprietary full‑wafer contact technology that enables simultaneous testing of entire wafers, reducing test time and cost compared with traditional probe‑card approaches. Its modular, platform‑based architecture allows rapid configuration for diverse device types, giving it flexibility that many larger competitors lack. While the industry is intensely competitive with established players possessing greater financial resources, Aehr differentiates itself through its patented wafer‑level contactors, die‑level carriers and a focus on high‑growth segments such as silicon carbide, gallium nitride, silicon photonics and AI accelerators.

The company sells its products to semiconductor manufacturers, semiconductor contract assemblers, electronics manufacturers, and burn‑in and test service companies worldwide. Its customer base is concentrated, with the five largest customers accounting for approximately 77% of net revenues in fiscal 2025, though no individual customer names are disclosed in the filing. Sales and service operations are located in the United States, Germany, Japan, the Philippines and Taiwan, with dedicated resources in China and South Korea and a global distributor network.

Investment Thesis

▲ Bull case

Aehr Test Systems is strategically positioned to capitalize on the structural shift toward wafer-level test and burn-in as semiconductor reliability becomes paramount in high-growth markets like silicon carbide, gallium nitride, and artificial intelligence processors. The company’s leadership in low-cost, proven wafer-level solutions—particularly its FOX platform—creates a durable competitive advantage as EV manufacturers and AI chipmakers demand extended burn-in times (up to 24 hours) to achieve sub-part-per-million failure rates, a requirement that package-level testing cannot economically satisfy. This is underscored by Gayn Erickson’s repeated emphasis on having tested more silicon carbide customer wafers than anyone, providing a unique data moat that validates their solution for automotive-grade quality. The stabilization in the silicon carbide market, coupled with EV suppliers shifting to integrated modules containing up to 32+ devices, directly increases the addressable market for Aehr’s wafer-level systems, as each module requires comprehensive pre-integration screening to prevent costly field failures in mission-critical applications like electric vehicles and data centers.
The acquisition of Incal Technology represents a transformative, underappreciated catalyst that expands Aehr’s addressable market beyond wafer-level test into high-value packaged part reliability solutions, particularly for AI processors, GPUs, and high-performance computing—markets where Incal’s ultra-high power capabilities (e.g., Sonoma system) are already generating volume production orders from hyperscaler data centers. This vertical integration enables Aehr to offer a turnkey reliability solution from engineering to high-volume production, a capability that competitors lack and that is increasingly critical as AI semiconductor complexity grows. Management’s note that Incal has a six-month lead time—longer than Aehr’s typical cycle—suggests that the current backlog of $16.6 million includes substantial, high-margin Incal orders not yet recognized as revenue, creating a hidden revenue spring that could materialize in Q2–Q3 FY25 as manufacturing consolidation at the Fremont facility progresses. The positive customer feedback on the acquisition, including increased forecasts for engineering and volume production from Incal’s existing AI industry leader base, signals immediate traction that is not being fully reflected in current guidance.
Aehr’s expansion into gallium nitride (GaN) power semiconductors and AI processors represents a multi-year structural growth opportunity that is being underestimated by the market, despite management’s cautious commentary. The company is in active negotiations for volume production wafer-level burn-in with its first GaN customer, supported by over a year of WaferPak deliveries for qualification across consumer, industrial, and automotive applications—markets where GaN’s forecasted 40% CAGR to over $2 billion in annual device sales by 2029 will drive sustained demand for burn-in. More significantly, the AI processor opportunity—where Aehr’s high-power FOX-XP system delivers over 2,000 amperes to a single 300mm wafer—is progressing rapidly with a customer that could become a >10% revenue contributor this fiscal year, with Gayn Erickson explicitly stating they are engaged with next-gen and future-gen processor teams and have a “front row seat” to roadmap evolution. The ability to leverage the same FOX platform for both silicon carbide and GaN, combined with Incal’s packaged part capabilities for AI, creates a unique, full-stack value proposition that few competitors can match, positioning Aehr to capture share as wafer-level migration accelerates in response to rising power densities and reliability demands in AI hardware.

Aehr Test Systems is strategically positioned to capitalize on the structural shift toward wafer-level test and burn-in as semiconductor reliability becomes paramount in high-growth markets like silicon carbide, gallium nitride, and artificial intelligence processors. The company’s leadership in low-cost, proven wafer-level solutions—particularly its FOX platform—creates a durable competitive advantage as EV manufacturers and AI chipmakers demand extended burn-in times (up to 24 hours) to achieve sub-part-per-million failure rates, a requirement that package-level testing cannot economically satisfy. This is underscored by Gayn Erickson’s repeated emphasis on having tested more silicon carbide customer wafers than anyone, providing a unique data moat that validates their solution for automotive-grade quality. The stabilization in the silicon carbide market, coupled with EV suppliers shifting to integrated modules containing up to 32+ devices, directly increases the addressable market for Aehr’s wafer-level systems, as each module requires comprehensive pre-integration screening to prevent costly field failures in mission-critical applications like electric vehicles and data centers.
The acquisition of Incal Technology represents a transformative, underappreciated catalyst that expands Aehr’s addressable market beyond wafer-level test into high-value packaged part reliability solutions, particularly for AI processors, GPUs, and high-performance computing—markets where Incal’s ultra-high power capabilities (e.g., Sonoma system) are already generating volume production orders from hyperscaler data centers. This vertical integration enables Aehr to offer a turnkey reliability solution from engineering to high-volume production, a capability that competitors lack and that is increasingly critical as AI semiconductor complexity grows. Management’s note that Incal has a six-month lead time—longer than Aehr’s typical cycle—suggests that the current backlog of $16.6 million includes substantial, high-margin Incal orders not yet recognized as revenue, creating a hidden revenue spring that could materialize in Q2–Q3 FY25 as manufacturing consolidation at the Fremont facility progresses. The positive customer feedback on the acquisition, including increased forecasts for engineering and volume production from Incal’s existing AI industry leader base, signals immediate traction that is not being fully reflected in current guidance.
Aehr’s expansion into gallium nitride (GaN) power semiconductors and AI processors represents a multi-year structural growth opportunity that is being underestimated by the market, despite management’s cautious commentary. The company is in active negotiations for volume production wafer-level burn-in with its first GaN customer, supported by over a year of WaferPak deliveries for qualification across consumer, industrial, and automotive applications—markets where GaN’s forecasted 40% CAGR to over $2 billion in annual device sales by 2029 will drive sustained demand for burn-in. More significantly, the AI processor opportunity—where Aehr’s high-power FOX-XP system delivers over 2,000 amperes to a single 300mm wafer—is progressing rapidly with a customer that could become a >10% revenue contributor this fiscal year, with Gayn Erickson explicitly stating they are engaged with next-gen and future-gen processor teams and have a “front row seat” to roadmap evolution. The ability to leverage the same FOX platform for both silicon carbide and GaN, combined with Incal’s packaged part capabilities for AI, creates a unique, full-stack value proposition that few competitors can match, positioning Aehr to capture share as wafer-level migration accelerates in response to rising power densities and reliability demands in AI hardware.

▼ Bear case

Aehr Test Systems faces significant near-term revenue pressure due to its extreme concentration in WaferPak sales, which accounted for 92% of Q1 FY25 revenue—a dramatic increase from 55% in the prior year period—revealing a troubling lack of diversification and over-reliance on a single product line that is vulnerable to customer inventory adjustments or shifts in procurement timing. This concentration is exacerbated by the company’s admission that it did not release a detailed backlog breakdown for Q1 FY25—the first time in eight quarters—specifically to avoid “triangulating” competitors, which obscures the true health of system sales and suggests weakness in core FOX-XP/NP system demand beyond WaferPak replacements. The reliance on WaferPak revenue as a recurring stream is questionable, as it depends entirely on customers utilizing their installed base for new designs; if new device qualification slows—as hinted by Gayn’s comment that customers are “forecasting” ramp-ups rather than reporting active production—this stream could deteriorate rapidly, leaving the company exposed to a sharp decline in top-line growth without a corresponding increase in system sales to offset it.
Despite optimistic commentary on silicon carbide, gallium nitride, and AI processors, Aehr has failed to convert its extensive customer engagements and benchmark programs into tangible, revenue-generating volume production orders, with management repeatedly framing opportunities as “forecasts,” “engagements,” or “evaluations” that are “progressing well” but lacking concrete commitments or timelines for meaningful financial impact. The silicon carbide opportunity, while framed as a long-term structural shift, remains dependent on EV suppliers finalizing capacity plans and OEMs standardizing on modules—a process Gayn acknowledged had been overly aggressive in prior years and is now only “aligning with physical buildings,” implying delayed timelines that may push material revenue contributions into FY26 or beyond. Similarly, the GaN and AI processor opportunities are described as “up-and-coming” with no disclosed customers, no named partners, and no disclosed pricing or volume expectations beyond vague references to a potential 10% customer—insufficient to justify current valuations given the company’s $13.1 million Q1 revenue and the high sales cycle lengths inherent in semiconductor test equipment, where qualification often takes 12–18 months before volume production begins.
The integration of Incal Technology presents material execution risks that are being downplayed, including potential cultural clashes, redundant overhead, and the challenge of merging two distinct sales motions—Aehr’s shorter lead-time wafer-level business versus Incal’s six-month lead-time packaged part business—which could disrupt Aehr’s historically efficient operations and erode margins if not managed flawlessly. Management’s plan to consolidate personnel and manufacturing into the Fremont facility by fiscal year-end is ambitious given the ongoing headquarters upgrade and remodeling, increasing the risk of operational delays, increased costs, or talent attrition during the transition. Furthermore, the fact that Incal’s customers—such as medical device manufacturers using the Tahoe system for FDA-traceable applications—have fundamentally different regulatory and sales cycles than Aehr’s traditional semiconductor base raises concerns about whether the combined entity can effectively cross-sell or achieve the promised synergies, especially since Gayn admitted that Incal’s current AI processor customers are “certainly different than any of Incal’s customers,” suggesting limited overlap and minimal immediate upside from the acquisition beyond absorbing Incal’s existing, low-growth revenue stream.

Aehr Test Systems faces significant near-term revenue pressure due to its extreme concentration in WaferPak sales, which accounted for 92% of Q1 FY25 revenue—a dramatic increase from 55% in the prior year period—revealing a troubling lack of diversification and over-reliance on a single product line that is vulnerable to customer inventory adjustments or shifts in procurement timing. This concentration is exacerbated by the company’s admission that it did not release a detailed backlog breakdown for Q1 FY25—the first time in eight quarters—specifically to avoid “triangulating” competitors, which obscures the true health of system sales and suggests weakness in core FOX-XP/NP system demand beyond WaferPak replacements. The reliance on WaferPak revenue as a recurring stream is questionable, as it depends entirely on customers utilizing their installed base for new designs; if new device qualification slows—as hinted by Gayn’s comment that customers are “forecasting” ramp-ups rather than reporting active production—this stream could deteriorate rapidly, leaving the company exposed to a sharp decline in top-line growth without a corresponding increase in system sales to offset it.
Despite optimistic commentary on silicon carbide, gallium nitride, and AI processors, Aehr has failed to convert its extensive customer engagements and benchmark programs into tangible, revenue-generating volume production orders, with management repeatedly framing opportunities as “forecasts,” “engagements,” or “evaluations” that are “progressing well” but lacking concrete commitments or timelines for meaningful financial impact. The silicon carbide opportunity, while framed as a long-term structural shift, remains dependent on EV suppliers finalizing capacity plans and OEMs standardizing on modules—a process Gayn acknowledged had been overly aggressive in prior years and is now only “aligning with physical buildings,” implying delayed timelines that may push material revenue contributions into FY26 or beyond. Similarly, the GaN and AI processor opportunities are described as “up-and-coming” with no disclosed customers, no named partners, and no disclosed pricing or volume expectations beyond vague references to a potential 10% customer—insufficient to justify current valuations given the company’s $13.1 million Q1 revenue and the high sales cycle lengths inherent in semiconductor test equipment, where qualification often takes 12–18 months before volume production begins.
The integration of Incal Technology presents material execution risks that are being downplayed, including potential cultural clashes, redundant overhead, and the challenge of merging two distinct sales motions—Aehr’s shorter lead-time wafer-level business versus Incal’s six-month lead-time packaged part business—which could disrupt Aehr’s historically efficient operations and erode margins if not managed flawlessly. Management’s plan to consolidate personnel and manufacturing into the Fremont facility by fiscal year-end is ambitious given the ongoing headquarters upgrade and remodeling, increasing the risk of operational delays, increased costs, or talent attrition during the transition. Furthermore, the fact that Incal’s customers—such as medical device manufacturers using the Tahoe system for FDA-traceable applications—have fundamentally different regulatory and sales cycles than Aehr’s traditional semiconductor base raises concerns about whether the combined entity can effectively cross-sell or achieve the promised synergies, especially since Gayn admitted that Incal’s current AI processor customers are “certainly different than any of Incal’s customers,” suggesting limited overlap and minimal immediate upside from the acquisition beyond absorbing Incal’s existing, low-growth revenue stream.

Statement Geographical Axis Breakdown of Revenue (2025)

Peer Comparison

Companies in the Semiconductor Equipment & Materials

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMAT	Applied Materials Inc /De	516.82 Bn	60.75	17.81	6.46 Bn
2	LRCX	Lam Research Corp	488.97 Bn	72.89	22.55	3.73 Bn
3	KLAC	Kla Corp	348.47 Bn	74.61	26.61	-
4	TER	Teradyne, Inc	66.84 Bn	70.06	17.65	-
5	Q	Qnity Electronics, Inc.	32.19 Bn	47.61	6.57	4.02 Bn
6	ENTG	Entegris Inc	25.16 Bn	94.72	7.78	3.65 Bn
7	AMKR	Amkor Technology, Inc.	19.80 Bn	45.18	2.80	1.41 Bn
8	FORM	Formfactor Inc	11.45 Bn	166.30	13.63	0.01 Bn

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Statement Geographical Axis Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Statement Geographical Axis Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password